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ABSTRACT

THE ROLE OF PROLACTIN IN REGULATING CCL28 EXPRESSION

Jennie “Sam” Hyde
Department of Microbiology and Molecular Biology
Master of Science

Infants are born with naive immune systems, making them susceptible to
a variety of infections. In order to protect the newborn infant it is important that
mothers be able to pass protective IgA antibodies to their infants through breast
milk. B cells that produce IgA enter the mammary tissue during lactation and secrete IgA into the milk. During pregnancy, the mammary tissue expresses high
levels of chemokines, molecules that allow lymphocytes to selectively home to
specific tissues. The chemokine CCL28 has been shown to be upregulated during both pregnancy and lactation, and is vital for the ability of IgA-producing B
cells to home to the mammary tissue during lactation. The aim of this study was
to determine whether CCL28 expression is regulated by prolactin signaling.
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I NTRODUCTION
In order to protect infants whose immune functions have not fully developed, there are several mechanisms by which a mother can pass on temporary
immunity. This transference of immunity is often mediated by antibodies, and can
happen both before birth and during lactation. The transferred immunity is the
result of cells in the immune system homing to specific tissues in order to secrete
antibodies. Many classes of molecules, including chemokines, are responsible for
this homing of immune cells. This study tested the hypothesis that the the lactogenic hormone prolactin up-regulates gene expression of the epithelial chemokine
CCL 28.

1.1

PASSIVE T RANSFER

OF I MMUNITY

Infants are born with immature immune systems; they are therefore far
more susceptible than adults to a variety of diseases, notably infections of the
gastro-intestinal tract. Evolution has therefore provided several protective mechanisms by which infants receive passive immunity from their mothers during this
critical period. Passive immunity is generally accomplished through the transference of products of an adaptive immune response, such as T cells or antibodies [1].
The receiving individual (in this case the infant) is protected, but does not produce
his or her own immune response. A passive transfer of immunity from mother
to infant can happen in two ways: either through IgG crossing the placenta before
birth, or via IgA passing through the breast milk and into the intestine of the infant
after birth. Both of these transfers are essential for protecting the infant during the
critical periods before birth and during immune development.
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1.1.1

IgG
IgG is the most common antibody in the serum [1]. It protects the blood

from pathogens, and is important in preventing systemic infections. IgG is the
only class of antibody that can cross through the placenta, and thus is the only
class of antibody transfered from the mother to the fetus before birth. IgG concentrations in the fetus gradually increase during pregnancy as neonatal Fc receptors
concentrate IgG inside the placenta. These Fc receptors have a higher affinity for
IgG than the receptors found in the mother, allowing IgG levels in the placenta
to be eventually higher than in the mother [2], [3]. Children born to hypogammaglobulinemic mothers (who lack normal immunoglobulin levels) are particularly
vulnerable to infection, as the mothers do not have antibodies to pass to the infant.
Although children born to such females may be born healthy, they are far more
likely to succumb to septicemia [4]. Gamma globulin is often administered to the
mother throughout pregnancy in order to protect the child, and the child is often
successfully treated with antibodies for six months after birth to prevent severe
illness. It has been suggested that intravenous IgG treatments administered to the
mother during pregnancy may also help the fetus mature normally, possibly by
preventing constant infection in the mother that might hinder fetal development
[4].
Even in children born to normal mothers protection through maternal IgG
is temporary. Passive immunity derived from maternal IgG wanes within the first
six months of an infant’s life as the antibodies are gradually degraded [2]. It is
thus critical that passive immunity be transferred to the infant during the time
between parturition and the development of the infant’s own memory responses
to pathogens in his or her environment.
1.1.2

IgA
Because the mucosal tissues line the respiratory, gastrointestinal and gen-

itourinary tracts, they are the point of entry for many pathogens. It is therefore
essential that these tissues have specific defenses to prevent infection. (Reviewed
2

in [5]). Without immune protection in these areas the body would be less able
to combat the large range of diseases entering through the mucosol layer. This is
demonstrated by the fact that individuals with IgA deficiency, the most common
immunodeficiency among people of European descent [6], experience more sinus
and pulmonary infections than normal individuals. Such individuals are surprisingly not more susceptible to gastro-intestinal (GI) tract infections; this may be due
to a compensatory mechanism that increases production of both IgG and IgM in
the GI tract [7].
Most classes of antibody are unable to cross through the epithelial layer into
mucosal tissues. Only IgA and IgM multimers, which have J chains that allow formation of multimeric complexes, can bind to the poly-Ig receptor (pIgR). Binding
of the J chain to pIgR allows the antibody/receptor complex to be endocytosed and
transported across the cell. Upon release, part of the pIgR is cleaved, and becomes
a secretory complex attached to the IgA dimer. (Reviewed in [5]). This component is
a glycoprotein, and allows the secretory IgA (sIgA) or IgM (sIgM) to pass through
harsh environments, such as the stomach, without being degraded. Many signals
in the body can up-regulate pIgR expression. Among these are several hormones
and inflammatory chemokines. The ability of inflammatory chemokines to increase
expression of pIgR during infection is crucial, as it aids transport of sIgA and sIgM
into the mucosal layer when they are most likely to be needed for protection.
Although some IgM can cross the epithelial wall, IgA is the primary antibody isotype in muscosal secretions and in breast milk in normal individuals. IgA
mediated passive immunity is passed to infants during nursing; this immunity is
critical in protecting the neonates from intestinal pathogens [8]. IgA is present in
the breast milk in concentrations between 0.5-1.5 g/l [9]. Although there is more
IgG in the blood, in normal individuals IgA is by far the most prevalent antibody
in the body. Infants who are not breast-fed, and thus do not receive IgA from their
mothers, are also far more susceptible to disease. In the developing world the death
rate among non-breast fed infants is significantly higher than among those infants
who are breast-fed. It is estimated that if all infants were breast-fed for the first
3

year of life, the number of infant deaths globally would decrease by one million
each year [10].
The antibodies passed from mother to child are specific to antigens found
in the mother’s (and, presumably, the child’s) environment. Because infants do not
have the memory responses typical of adult immunity, it has been suggested that
immunizing the mother against childhood infections, such as pertussis, might be
an effective method of preventing infection in the neonate. In animal studies this
has been shown to be effective, as piglets who suckle mothers that have received
pertussis vaccinations are far less susceptible to serious infection [11]. The IgA in
breast milk plays a crucial role in this defense, although other components of breast
milk also protect the infant [11].
1.2

LYMPHOCYTE HOMING AND

CHEMOKINES

Lymphocyte migration into specific tissues happens through a multi-step
process. (Reviewed in [12]). This process is controlled through the expression of several different classes of homing molecules. The most important of these molecules
are the selectins, integrins and chemokines (Table 1.1).
Different selectins are found on both lymphocytes and on the endothelium.
They are glycoproteins that have the ability to bind heavily glycosylated molecules,
such as mucins, in a receptor/ligand binding process. Mucins are also expressed
by both lymphocytes and the endothelium. The interaction between selectins and
mucins results in the “tethering,” of the lymphocyte to the endothelial wall. This
is a loose interaction, and is not enough to stop the movement of the lymphocyte, although it does slow the cell, allowing it to roll along the endothelial wall.
This rolling allows the lymphocyte to be exposed to the chemokines being produced by the tissue. If the lymphocyte has the correct chemokine receptor it will
become activated, allowing the cell to migrate across the endothelium. Without
this chemokine-mediated activation the cell will continue to roll through the blood
vessel, and never enter into the tissue.
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Molecule

Ligand

Action

Location

Selectin

Heavily
glycolsylated
molecules, such
as Mucins

Initial tethering,
rolling of
lymphocyte,
weak adhesion

Endothelial wall:
E- and Pselectins

Integrins

Cellular
Adhesion
Molecules (Ig
superfamily)

Firm adhesion

Leukocytes

Cellular
Adhesion
Molecules CAMS

Integrins,
Selectins

Firm adhesion

Endothelial wall

Chemokines

Chemokine
receptors on
leukocytes

Activation,
diapedesis and
migration

Produced by
tissue

Table 1.1: Important homing molecule classes [1]

Chemokines are a subset of cytokines identified by four highly conserved
cysteine residues. They are classified according to the position of the cysteine residues; most are either “CC chemokines” or “CXC chemokines,” although other classes
exist. Chemokines can be produced either constitutively or in response to inflammation, and bind to seven trans-membrane G-coupled receptors. (Reviewed in [12]).
Activation of a cell by chemokine binding results in a change in integrin conformation. This change allows the integrins to bind ligands more effectively, which
results in a firm adhesion of the lymphocyte to the endothelial wall. Integrins
are heterodimers, and bind to another class of molecules, the Cellular Adhesion
Molecules (CAMS). The firm adhesion caused by the binding of integrins and
CAMs allows the lymphocyte to leave the blood vessel and enter the tissue, where
it can migrate up a chemotactic gradient toward the cells producing the chemokines (Figure 1.1). During pregnancy and lactation, many adhesion molecules and
chemokines are expressed by the mammary tissue, allowing more lymphocytes to
5

enter the mammary gland [13], [14], [15]. This compliment of adhesion molecules
and chemokines mediate the homing and accumulation of IgA antibody secreting
cells (ASC) to the lactating mammary gland.

Figure 1.1: Multi-step lymphocyte homing model. Adapted from [12].

1.2.1

Chemokines mediating IgA ASC migration
Because IgA ASCs must migrate into the mucosal tissues in order to func-

tion effectively, these tissues express specific chemokines that mediate this migration. In particular,

CCL 25

and

CCL 28

are known to be critical chemokines that at-

tract IgA ASCs. In some tissues, such as in the lamina propria (LP) of the small
intestine, these two chemokines may play similar roles, as they both are expressed
and serve to attract the same cells. The redundant role played by CCL 25 and CCL 28
is demonstrated by the fact that, if either chemokine is blocked by antibodies, the
IgA ASCs are still able to home to the LP. If both are blocked, however, IgA ASCs
are unable to migrate into the tissue [16]. In other tissues the expression and function of CCL 25 and CCL 28 differ dramatically. In the mammary tissue, for example,
CCL 28

plays a critical role in attracting IgA ASCs during pregnancy and lactation,
6

while CCL 25, although expressed, does not appear to play a large role in IgA ASC
homing to this tissue.
1.3

CCL 25
CCL 25,

also known as thymus-expressed chemokine (TECK), is expressed

largely in the thymus and small intestine. It binds to the chemokine receptor CCR 9,
which is expressed by IgA ASCs, as well as by a subset of T cells [16], [17]. CCL 25 is
not expressed in the large intestine, however, which may allow more lymphocytes
expressing

CCR 9

to home directly to the small intestine. This results in a more

specific and localized immune response in these tissues.
1.4

CCL 28

One molecule that is important in IgA ASC homing to the large intestine
and mammary tissues is CCL 28, also known as mucosae-associated epithelial chemokine (MEC). CCL 28 is a “CC” chemokine that is expressed by epithelial cells in
the mucosal tissues, and is known to bind to the receptors CCR 3 and CCR 10 [18].
CCR 3

has been shown to be expressed by eosinophils, and may contribute

to eosinophil accumulation in asthmatic conditions, as

CCL 28

is known to be up-

regulated in the lung after allergen exposure [19]. In vivo studies have also shown
that CCL 28 is significantly up-regulated in human colon explants during infection,
potentially helping to attract lymphocytes to the area of infection. Similarly, when
bacterial proteins were added to tissues, the levels of CCL 28 increased dramatically
[20]. The pro-inflammatory cytokines Il-1β and TNF-α were shown to up-regulate
CCL 28

in the lung and may be responsible for up-regulating

CCL 28

levels under

asthmatic conditions or during bacterial infection.
The other receptor for
[21].

CCL 28

CCL 28, CCR 10,

is expressed primarily on IgA ASCs

mediates migration by IgA ASCs, but does not have a great effect on

IgG secreting cells [22]. This suggests that CCL 28 primarily affects cells producing
antibody destined to be secreted into the mucosal membranes, and that the expression of CCR 10 is responsible for selecting only IgM and IgA producing B cells.
Since secretory IgM and IgA are the primary antibodies in breast milk, the B cells
7

producing these isotypes must be able to home selectively to mammary tissues.
The fact that IgG cells do not express

CCR 10

demonstrates the selectivity of the

homing process.
In 2004, Wilson and Butcher showed that
the mammary tissue during pregnancy, and

CCL 28

CCL 28

is clearly up-regulated in

is up-regulated even more

significantly during lactation. They also demonstrated that anti-CCL 28 antibodies blocked IgA ASCs from homing to the mammary tissue [13]. This clarified the
importance of

CCL 28

in lymphocyte homing, although the exact mechanism by

which CCL 28 is up-regulated was not shown. This work also demonstrated the absolute necessity for

CCL 28

up-regulation; without

CCL 28

the lymphocytes could

not home to the mammary gland, and the mother could not pass IgA mediated
immunity to her infant. This, in turn, clearly demonstrates the critical nature of
CCL 28

1.5

expression in infant protection through maternal antibody transfer.

L ACTOGENIC H ORMONES
During pregnancy and lactation there are increased levels of hormones pres-

ent in the mother’s body. These hormones are responsible for many crucial tasks,
including maintaining pregnancy, remodeling mammary tissue, and stimulating
milk production. It has been shown that some hormones are responsible for changes
in immune function. For example, In 2003, Peeva et al. demonstrated that prolactin,
a hormone produced in high levels by the anterior pituitary during pregnancy and
lactation, is able to effect the survival of B cells in vivo [23]. The hormones produced during pregnancy often work synergistically to increase gene expression.
Some genes (such as the milk protein β-casein) require that both prolactin and cortisol be present in order for strong expression to be induced, although each can
induce low levels of gene expression alone [24].
Many hormones are responsible for mammary tissue remodeling and milk
production during first pregnancy and then lactation. Among these are glucocorticoids, which are steroid hormones, and prolactin, a peptide hormone.

8

1.5.1

Cortisol
The main glucocorticoid in humans is cortisol, while corticosterone plays a

greater role in mice [25]. Cortisol is mainly produced in the adrenal gland. Its production is stimulated by the presence of the adrenocorticotropic hormone (ACTH),
which is in turn stimulated by corticotropin releasing hormone (CRH), which is
produced by the hypothalamus (Figure 1.2). An over-abundance of cortisol, whether
natural, as in the case of an ACTH or CRH producing tumor, or artificially introduced will result in decreased immune responses. This decrease can be useful
clinically for decreasing the inflammation associated with inappropriate immune
responses, such as the hypersensitivity reactions that cause asthma [26].

Hypothalamus
Cortisol

–

CRH

+

ACTH

Anterior Pituitary

+

Adrenal Gland

Cortisol

–

Cortisol

Immune Function
Metabolism
Fat depostition
Etc.

Figure 1.2: Cortisol Production [25].
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Glucocorticoids are necessary for immune function. They are important regulators of immune cells, influencing their longevity and efficacy in the tissues. It is
important to appreciate, however, that glucocorticoids also have a much broader
role outside the immune system. Glucocorticoids influence gene expression of cells
throughout the body, and are important in many different biological pathways.
They can influence fat disposition, bone mineralization, and alter the body’s ability to metabolize sugar [25].
Cortisol levels gradually increase throughout pregnancy [25]. A sharp increase of cortisol shortly before parturition directs the fetus’ lungs to start producing surfactant, which is necessary for survival after parturition [25], [27]. Premature animals who are administered cortisol before parturition are able to expand
their lungs while untreated animals induced at the same time cannot [28]. It has
been postulated that the natural increase of cortisol shortly before parturition may
also significantly, although temporarily, alter immune function in the mother [29].
In human breast and intestinal cell lines, glucocorticoids also have the ability to increase expression of pIgR [5]. In animal models, however, glucocorticoids
are only effective when prolactin is also present. The increased pIgR expression
allows for greater transport of sIgA into these areas, providing greater protection
of the tissue and secretion of antibodies into the breast milk [5], [30].
1.5.2

Prolactin
Most of the prolactin in the body is produced by the anterior pituitary in

response to a number of signals, including oxytocin, thyroid releasing hormone
(TRH), and other hormones, many of which are produced in the hypothalamus.
Prolactin is normally under negative control by dopamine, which is also produced
in the hypothalamus. Prolactin is, in fact, the only hormone in the anterior pituitary
under constant negative control by dopamine produced in the hypothalamus [25],
[31] (Figure 1.3).
In addition to the prolactin produced by the anterior pituitary, small amounts
of decidual prolactin are produced by the endometrium throughout pregnancy;

10

Hypothalamus

Oxytocin
TRH
ADH
Etc.

Dopamine or
Dopamine Agonist

–

+

Prolactin
Anterior Pituitary

+

Mammary Tissue

Immune Function
Breast Tissue Remodeling
Milk Synthesis

Figure 1.3: Prolactin Production [25]

this production is not subject to dopamine agonist receptor inhibition [32]. Decidual prolactin is, however, produced at far lower levels than the prolactin produced
in the anterior pituitary, and cannot compensate for a cessation of pituitary prolactin production.
Prolactin production by both the maternal anterior pituitary and the fetus
increases throughout pregnancy, with a sharp increase in maternal production that
occurs when nursing begins. The increased levels of prolactin present during pregnancy play an important role in restructuring the mammary tissue in order to allow
it to become a functional lactogenic gland [33].
Significantly, prolactin has also been shown in animal models to up-regulate
the expression of pIgR in the mammary gland [5], [30]. Because pIgR allows IgA to

11

cross into the breast milk, this is one method by which prolactin helps to increase
the transfer of immunity from mother to child.
1.5.2.1

β-casein
Prolactin is an important stimulator of milk proteins. In this study we chose

to use the milk protein β-casein as a control because the expression of this protein
is so dependent on prolactin that it acts as an endogenous control to indicate that
prolactin is signaling. Prolactin stimulates β-casein expression through the Jak2Stat5 signaling pathway; In vivo the expression of β-casein is increased by a factor
of 2.5 when prolactin is added to cell cultures treated with glucocorticoids and
insulin [34]. This increase is believed to be due to phosphorylation of Phosphorylated Heat- and Acid-Stable protein regulated by Insulin (PHAS-I). When prolactin
is added to cell culture, PHAS-1 is phosphorylated, releasing eIF4E, which is a capbinding protein that stimulates translation of mRNA [34].
Even more significantly, the addition of prolactin to cell cultures treated
with glucocorticoids and insulin can increase the stability and accumulation of
β-casein mRNA by seventy-five fold [34]. This increase in stability is due to increased polyadenylation of the mRNA. Kuraishi et al. demonstrated that the βcasein mRNA poly(A) tail in the mammary gland exists in two forms. β-casein
mRNA with a long poly(A) tail has a significantly longer half-life than mRNA with
a shorter poly(A) form [35]. It is thought that the adenylation protects the mRNA
from ribonucleases [35].
1.5.2.2

Inhibition of prolactin release
Dopamine receptor agonists bind to dopamine receptors, preventing pro-

lactin release. One of the most common dopamine receptor agonists is bromocryptine. Administering bromocryptine to an animal dramatically decreases prolactin
production by activating the D2 receptor [36]. This is used clinically to treat patients with lactotroph tumors that produce too much prolactin. Bromocryptine
treatment often results in both decreased prolactin production and decreased tumor size. (Reviewed in [37]).
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Bromocryptine is also used in research to determine what effect prolactin
has. By removing prolactin from the system through bromocryptine administration, it is possible to see which genes require prolactin signaling in order to be
expressed. For example, because prolactin regulates pIgR [5], blocking prolactin
release with bromocryptine may decrease pIgR expression.
Although previous studies have investigated the role prolactin plays in regulating parts of the immune system, its role in regulating CCL 28 expression has not
been identified. Similarly, studies of mammary CCL 28 expression have shown that
CCL 28

is up-regulated during times when prolactin levels are high, but has not

demonstrated that this up-regulation is due to prolactin signaling. Discovering the
relationship between the hormone and chemokine will increase understanding of
how chemokine expression is regulated, and the process by which IgA ASCs enter
the mammary gland.

1.6

R ELEVANCE
It is important to understand how homing molecules are regulated during

pregnancy and lactation. If the mechanisms by which IgA producing cells are recruited to mammary glands are elucidated, it may be possible to design vaccines
that are more effective at passing immunity to nursing infants. Immunizations today are often able to confer protection on the infant [38], [39], but it is not well understood why some vaccines work better then others in this arena. Current studies
on immunization through breast milk are generally observational, and seek to see
if an already-developed vaccine will confer immunity or not, rather then describe
the mechanisms by which IgA ASCs are induced to home to mammary tissue. By
characterizing the methods by which IgA ASCs home to the mammary tissue to
produce IgA which protects the infants, the potential for designing more effective
vaccines will be greatly increased.
In addition, understanding the basic biology of adhesion molecule gene
regulation may help researchers find ways to block lymphocyte homing in cases
where the homing is inappropriate, as is the case in many autoimmune diseases.
13

In many of these diseases, lymphocytes home inappropriately to tissues in which
they are not needed and cause significant inflammation and tissue damage. The
current treatment regime for such diseases generally consists of administering
large doses of corticosteroids to the patient; these corticosteroids knock out beneficial immune responses as well as inappropriate ones. Understanding why lymphocytes migrate to specific tissues will help researchers discover more precise
methods of treating such conditions.
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M ATERIALS

2.1

AND

PCR AND

M ETHODS

Q UANTITATIVE PCR

RNA was extracted using a modification of Invitrogen’s (Carlsbad, CA)
Trizolr protocol. RNA was quantified using a Nanodropr spectrometer. The Applied Biosystems (Foster City, CA) GeneAmp PCR Core Kitr was used for PCR reactions. The Quantitative PCR was run using the Taqman One-Step RT- PCR Master
Mix Reagents.r
2.1.1

RT- PCR

GAPDH

was used as an endogenous control.

primers

Primers for the RT- PCR experiments were designed using Invitrogen’s Oligoperfect Design™ program. Two primer sets were designed for each gene. Both sets
of primers were tested on mouse tissue, and the most effective primers were chosen for subsequent gene amplification. Primer sets used in experiments are listed
below.

2.2

C ELL CULTURE
In order to determine what effect prolactin has on mammary epithelial cell

gene expression, in vitro studies were performed. Because immortalized cell lines
do not always express the same genes as the original tissue, two cell lines were
used, thus decreasing the chances that results from the in vitro studies were simply
an artifact of the cells’ transformation.
HC 11 and NOG 8 cell lines are transformed murine mammary epithelial cells.
HC 11 cells were a gift from Dr. Jeffrey Rosen, (Baylor college of medicine) and used

with the permission of Dr. Bernd Groner (Institute for Biomedical Research, Frankfurt, Germany).

NOG 8

cells were donated by Dr. Barbara Vonderhaar (NIH). Both

cell lines were initially grown using a protocol provided by Dr. Carrie Shemenko
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Gene

Primer Sequence

CCL 25

CGA GGC GCT AGC GCA AGG TGC CTT GAA GA
CGA CCG GAT CCG CAT TGT TGG TCT TTC TGC
GAA CAC GTG GAA CAC ACA GG
TTG TTT TGC TTT TGG TGC TG
CCA CCC AGA AGA CTG TGG AT
CAC ATT GGG GGT AGG AAC AC
GCA CCT TCC TCA GTC TCT GG
TGT GGA AGG AAG GGT GCT AC
TGC TAA ACC CCC AGA TTA CG
GGC TGA TTC CTC AAG CAA AG
TCA CAG CAG CAC ATC AAC AA
TGT CCT CAT CCT GGA AGG T
AAG ATG GAG GAA GGC AGT T
GAT CCT GGA GGG AAG AGA C

forward
reverse
CCL 28 forward
CCL 28 reverse
Gapdh forward
Gapdh reverse
β-casein forward
β-casein reverse
Prolactin receptor forward
Prolactin receptor reverse
Il-1β forward
Il-1β reverse
TNF-α forward
TNF-α reverse
CCL 25

Table 2.1: Forward and reverse PCR primers.

(University of Calgary). Cells were grown to confluency at 37 °C with 5% CO2 in
RPMI media containing 10% Newborn Calf Serum (NCS), 50 units/ml penicillin,
50 units/ml streptomycin, 10ng/ml recombinant human epidermal growth factor
(EGF) and 5ug/ml insulin. At confluency the cells were washed three times with
media not containing EGF, and given priming media. This priming media is prepared as before, except that EGF is not added. In this protocol cells are kept in this
priming media for either one or four days, and then given 0.1µM dexamethasone
along with 5µg prolactin. RNA is extracted after six hours incubation with these
hormones.
In the second

HC 11/ NOG 8

protocol, cells are grown to confluency as be-

fore. At confluency they are kept in priming media for 48 hours, then given 1µM
dexamethasone. New priming media and dexamethasone are added once a day
for four days, then cells are incubated with 1µM dexamethasone and 5µg/ml prolactin. RNA is extracted twenty-four hours after prolactin and dexamethasone are
added.
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In both protocols β-casein was used as an internal control. β-casein is known
to increase if prolactin is signaling, so it was possible to demonstrate that the protocol was working whether or not CCL 28 expression changed.
Il-1β has been shown to up-regulate

CCL 28

in human lung cancer cells. To

determine if Il-1β had the same effect in murine mammary cells,

HC 11

cells were

grown until confluent as above. Cells were then incubated with 10ng/ml Il-1β
(purchased from Peprotech (Rock Hill, NJ)) at 37 °C with 5% CO2 for six hours.
After six hours RNA was extracted as above.
Macrophages produce Il-1β in vivo. We therefore sought to determine whether
macrophages were capable of producing sufficient Il-1β to increase CCL 28 in mammary tissue. We used both a macrophage cell line and peritoneal macrophages
taken from a mouse.
The transformed

RAW

macrophage cell line was grown in DMEM supple-

mented with L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin.
When RAW cells were added to the HC 11 cell line the cells are grown in HC 11 media for twenty-four hours before being treated with prolactin as described above.
Peritoneal macrophages were obtained by washing the abdominal cavity
of a mouse with saline solution. These macrophages were then added directly to
confluent HC 11 cells.

2.3

In Vivo STUDIES
In vivo studies, while valuable as cell culture systems, cannot precisely mimic

conditions in live animals. We therefore performed in vivo studies to determine
what effect prolactin inhibition through bromocryptine had on CCL 28 expression.
In order to do this, we injected lactating mice with bromocryptine, and determined
the change in CCL 28 gene expression. Once again, β-casein was used as an internal
control to show that bromocryptine was effectively decreasing prolactin levels in
the mouse.
Bromocryptine was purchased from Sigma-Aldrich (St. Louis, MO). Bromocryptine hydrolyzes in water, so we initially reconstituted it in 100% ethanol at four
17

times the concentration needed, and stored this solution at -80 °C. The stock solution was then diluted to the proper concentration on the day it was to be injected
into the animal.
Female mice were treated by one of two methods. In the first method, mice
were injected intraperitoneally with 800 µg bromocryptine in a total injection volume of 200µl. The mice were injected for two days beginning on day eleven after
parturition. The bromocryptine was made in ethanol and water as above, and RNA
was extracted using the same protocol (Figure 2.1).
In the second method, mice were injected intraperitoneally with 400 µg bromocryptine for six days beginning on day eight after parturition. This day was
chosen because milk production is high, and
decrease in β-casein or

CCL 28

CCL 28

is strongly expressed, so any

would be both noticeable and significant. The bro-

mocryptine was made up in 1:3 ethanol stock solution to water, with a total injection volume of 200µl. On the seventh day the after injections begin mice are
sacrificed, and their mammary and salivary gland tissue is removed (Figure 2.2).
RNA from these tissues was extracted as above.
2.4
2.4.1

S TATISTICAL ANALYSIS
In vitro
In the in vitro studies, multiple wells that had been treated concurrently with

the same treatment protocol were pooled together to reduce error from individual
aberrant samples. The experimental samples were compared against samples from
the ethanol and water injected control mice in the Q - PCR; the Q - PCR protocol sets
the gene expression in the control samples as the zero against which all experimental data was compared. For analysis, all dexamethasone and all prolactin data
were averaged together. A student’s t-test analyzed the β-casein and

CCL 28

ex-

pression changes in both the dexamethasone and prolactin treatments. The t-test
tested specifically the significance of the experimental data’s mean not being zero.
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2.4.2

In vivo
As with the in vitro studies, all data was compared to RNA from control an-

imals that were set as the baseline level for gene expression. The data from the in
vivo experiments were then analyzed by three separate methods. In the first analysis method, all of the experimental data points for each mouse were averaged
together, so that each mouse had an individual average for the change in both βcasein and

CCL 28

expression levels. This insured that each mouse was weighted

equally in the final average, despite the fact that more data was collected from
some mice. All of the experimental mice were then averaged, as were all of the
control mice. These final averages were tested for significance. The t-test tested
the significance of the change in gene expression’s not being zero. In the second
method, all of the experimental data points for each mouse were not averaged
together, so that each experimental data point was treated equally, regardless of
which mouse the data originated from. The experimental data points and the control data were then all averaged together, giving a final average for each. These
final averages were tested for significance. As before, the t-test tested the significance of the change in gene expression’s not being zero. The third method of analysis took into account the large variance in the control samples. All of the control
samples were compared to all of the experimental samples. A student’s t-test was
carried out to determine whether there was a significant difference between the experimental and control data. This t-test was carried out assuming equal and assuming unequal variances; there was little difference between the two. All presented
data will assume unequal variances between control and experimental data.
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Figure 2.1: Mice are injected with either bromocryptine or a control for two days, starting on day 11 after birth. Mice are sacrificed on day 13, and RNA is extracted for analysis by q- PCR
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Figure 2.2: Mice are injected with either bromocryptine or a control for six days, starting on day 8 after birth. Mice are sacrificed on day 14, and RNA is extracted for analysis
by q- PCR
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R ESULTS

3.1

I L -1β
Il-1β has been shown to up-regulate CCL 28 in lung tissue [40]. Accordingly,

we sought to determine if the increase in CCL 28 expression in the mammary gland
was mediated by Il-1β. Il-1β has been shown to be up-regulated by prolactin in
vitro [41]. In order to determine whether Il-1β can up-regulate CCL 28 in mammary
tissue,

HC 11

cells were treated with 10ng/ml Il-1β.

RT- PCR

analysis showed no

expression of CCL 28 in treated or untreated cells (Figure 3.1).
Although Il-1β did not appear to have a direct effect on

HC 11

mained possible that the Il-1β added was not sufficient to induce
sion, or that

CCL 28

cells, it re-

CCL 28

expres-

expression is dependent on Il-1 in conjunction with other cell

derived factors. Macrophages produce Il-1 in vitro upon stimulation with prolactin
[42]. An analysis of

RAW

cells by

PCR

demonstrated that the cells express pro-

lactin receptor and Il-1β. In an effort to determine if macrophages treated with
prolactin would produce enough Il-1β to induce
were co-incubated with
co-incubation of

RAW

RAW

and

CCL 28

expression,

HC 11

cells

cells with and without prolactin (Figure 3.2). The

HC 11

cells treated with hormones did not increase the

expression of CCL 28. Since RAW cells are a transformed cell line, and thus may react
differently to prolactin stimulation than wild type macrophages, peritoneal macrophages taken from a mouse were also co-incubated with HC 11 cells in the same
manner. These macrophages also failed to up-regulate CCL 28 (data not shown).
Finally, to demonstrate that Il-1β was not responsible for the increase of
CCL 28

in pregnancy and lactation in vivo, mammary tissue from both virgin and

lactating mice were examined. Presumably, if Il-1β is responsible for the change
of CCL 28, the levels between virgin and lactating mice would be dramatically different. Il-1β levels between the virgin and lactating mice remained similar, with a
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Il-1β Treatment

GAPDH

CCL28

CCL28

GAPDH

CCL25

CCL25

No Treatment

(a)

HC 11

cells alone.

(b)

HC 11

+ RAW cells.

(c) HC 11 +
treatment.

RAW

pIgr
pIgr

GAPDH
GAPDH

β-Casein

CCL25
25
CCL

CCL28

pIgr
pIgr

GAPDH
GAPDH

β-Casein
β-Casein

CCL25
25
CCL

CCL28

pIgr

GAPDH
GAPDH

β-Casein

CCL25
25
CCL

CCL
CCL28
28

Figure 3.1: Il-1β does not up-regulate CCL 28 expression in HC 11 mammary epithelial
cells. HC 11 cells were grown until confluent, as described in materials and methods.
10ng/ml Il-1β were then added for six hours. RT- PCR analysis revealed no detectable
changes in CCL 28 or CCL 25 expression following this treatment.

+ prolactin

Figure 3.2: HC 11 cells co-incubated with RAW macrophage cells and/or prolactin.
CCL 28 was not up-regulated by either RAW cells or prolactin treatment.
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small increase happening during lactation (Figure 3.3). The fact that there was a
small increase in Il-1β in the mammary gland, but Il-1β is not capable of stimulating

CCL 28

in vitro suggests that Il-1β probably is not directly responsible for the

increase in CCL 28 seen in lactation.

GAPDH

Il-1β

TNF-α

Lactating Mouse

GAPDH

TNF-α

Il-1β

Virgin Mouse

Figure 3.3: Virgin and lactating mouse expression of Il-1β, TNF-α and Gapdh. Il-1β
expression in the lactating mammary gland does not increase sufficiently to be responsible for the change in CCL 28 expression.

3.2
3.2.1

P ROLACTIN SIGNALING in vitro
HC 11

cells treated with prolactin

HC 11

cells are an immortalized murine mammary tissue cell line known

to produce the milk protein β-casein upon stimulation with prolactin [43]. Two
protocols were used to determine what effect prolactin and/or corticosteroids had
on CCL 28 expression in vitro.
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The first protocol required

HC 11

cells to be grown to confluency in media

containing the hormones EGF and insulin (see materials and methods). Although
necessary to properly prime the cells, EGF is known to block β-casein expression;
therefore, confluent cells were washed and given media containing only insulin
[44]. After at least twenty-four hours in this priming media, prolactin and dexamethasone were added.
This protocol resulted in the up-regulation of β-casein expression, but not
of CCL 28. This suggests that prolactin may not be responsible for changes in CCL 28
levels, or that another hormone not present in the in vitro model is needed.

GAPDH

β-Casein

CCL25

CCL28

Prolactin Treatment

GAPDH

β-Casein

CCL25

CCL28

Control

Figure 3.4: HC 11 cells treated with dexamethasone and 5µg prolactin. The hormone
treatment successfully up-regulated β-casein, demonstrating that both the dexamethasone and prolactin were signaling, but failed to change the expression of CCL 28.
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3.2.1.1

HC 11

mammary epithelial cells pre-treated with dexamethasone

Lee et al. showed that

HC 11

cells transfected with bovine casein required

pretreatment with dexamethasone to be able to induce bovine casein expression
[45]. To determine whether pretreatment with dexamethasone would aid expression of both β-casein and

CCL 28, HC 11

cells were pre-treated for four days with

1µM dexamethasone before treatment with either dexamethasone alone or with
dexamethasone and prolactin.
This course of treatment did not result in a significant up-regulation of βcasein in cells treated with dexamethasone and prolactin, as measured by QPCR.
(Table 3.1). The significance of the mean change of β-casein expression not being
zero for dexamethasone alone or for dexamethasone and prolactin was p= 0.41
and p=0.17, respectively. This suggests that either prolactin was not signaling or
that the dexamethasone treatment actually had an inhibitory effect on β-casein
expression.
Interestingly, the average change in

CCL 28

expression in dexamethasone

treated cells was highly significant (p<0.01), as was the change in

CCL 28

expres-

sion in the prolactin treated cells (p<0.01). The fact that the dexamethasone treatment alone was able to change

CCL 28

expression significantly suggests that cor-

ticosteroids have an independent effect on

CCL 28

expression in vitro. Because β-

casein expression did not change in prolactin treated cells, it is not possible to
determine whether or not prolactin was signaling. It appears that the change in
CCL 28

expression can therefore be attributed only to the dexamethasone signal-

ing.
3.2.2

NOG 8

The NOG 8 line is also a murine mammary cell line. It has been used by Vonderhaal et al. to study the effect of prolactin signaling in vitro. NOG 8 cells, however
have not been extensively used to study milk protein production.
NOG 8

cells were treated with the protocols described for

HC 11

cells. The

first protocol failed to produce a noticeable change in β-casein expression (data
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Treatment
Dex
Dex
Dex
Prl/Dex
Prl/Dex
Prl/Dex
Dex (average)
Prl (average)

Beta-casein

CCL 28

−0.53 ±0.10 1.31 ±0.08
0.18 ±0.03 0.26 ±0.05
0.07 ±0.20 0.04 ±0.09
−1.30 ±0.18 0.13 ±0.51
0.51 ±0.25 0.57 ±0.08
−0.02 ±0.04 0.51 ±0.03
−0.02 ±0.12 0.58 ±0.18*
−0.24 ±0.26 0.43 ±0.14*

Table 3.1: Average change in gene expression as measured by QPCR of CCL 28 and βcasein in HC 11 cells treated with either dexamethasone alone (dex), or dexamethasone
and prolactin (Prl). * Denotes a statistically significant finding. As always, all data
points were compared to an endogenous control during analysis.

not shown). This may partly be explained by the fact that very low levels of βcasein are already produced in untreated

NOG 8

cells, making it more difficult to

determine changes in the gene expression. It is not clear whether these cells are
able to be induced to produce more β-casein under any treatment.

CCL 28

expres-

sion was also not significantly changed during the hormone treatment (data not
shown).
3.3

In vivo INHIBITION OF PROLACTIN
In vitro studies of endocrine interactions often are unable to reproduce con-

ditions present in an animal. To test the effect of prolactin on CCL 28 expression in
vivo, we administered the dopamine agonist bromocryptine to lactating mice. This
allowed us to determine whether or not CCL 28 expression changes in the absence
of prolactin. Once again, β-casein served as an endogenous control, allowing us to
ensure that the bromocryptine was effectively blocking prolactin production.
Two different courses of treatment were followed. The first began on the
eleventh day post-parturition, and consisted of two mice injected with 800µg of
bromocryptine diluted in 25% ethanol, and two mice injected with a 25% alcohol
control as above. These treatments were administered for two days. The mice were
sacrificed on the third day.
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The second treatment began on day eight post-parturition. This was a seven
day treatment in which mice were injected with 400µg bromocryptine each day
for six days, and sacrificed on the seventh day. The injections began on the eight
day post-parturition. There were five experimental mice, and two control mice.
The control animals were injected with a 25% alcohol control. In subsequent subsections all quantitative results are given on a logarithmic scale.
3.3.1

Six day treatment
The six day treatment course was successful at decreasing β-casein, although

individual mice varied as to how much the expression changed. Interestingly, CCL 28
was generally more sensitive to the effects of bromocryptine than β-casein was (Table 3.2 and Figures 3.6 and 3.5).

Mouse

Beta-casein

F
−1.24 ±0.41
G
−0.24 ±0.22
H
−0.06 ±0.22
J
−1.81 ±0.29
L
0.24 ±0.40
All treated mice −0.67 ±0.25*
Control mice
0.83 ±0.41

CCL 28

(MG)

CCL 28

(SG)

−2.32 ±0.27
ND
−2.30 ±0.36 −0.63 ±0.14
−0.37 ±0.38 −0.53 ±0.17
−0.28 ±0.25
2.34 ±0.33
−0.31 ±0.52
0.12 ±0.52
−1.31±0.23*
0.22 ±0.28
−1.19 ±0.47 -1.25 ±0.56

Table 3.2: Average change in gene expression of CCL 28 and β-casein in the mammary
gland (MG) and salivary glands (SG) of mice treated with bromocryptine for six days.
Data is from multiple QPCR reactions run on RNA from each mouse. The average
number is listed in the table plus or minus the standard error.

3.3.1.1

Analysis of weighted averages
This analytical method weighted all of the mice evenly against each other.

This meant that if one mouse had more samples than another, they would still each
be evenly represented in the analysis. The downside of this analytical method was
that, because averages were used instead of individual data points, the total num-
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ber of data points being analyzed was much lower, resulting in decreased certainty.
The averages of each mouse were then averaged together for a final average.
In the mammary tissue, β-casein expression decreased an average of -0.84
(almost ten times). Due to mouse-to-mouse variation, the variablity of these results
was high, with a standard error of 0.41. A Student’s t test analyzed whether or
not the average decrease in β-casein was significantly different from zero, the null
hypothesis mean. The p value (one tailed) from this test was 0.054.
The average change in CCL28 expression in the mammary gland was -1.29,
with a standard error of 0.46. A student’s T test gave the significance of CCL28
not being zero as p=0.025 (one tailed), suggesting that in vivo CCL28 may be more
sensitive to prolactin changes than β-casein. It was puzzling that the decreases in
β-casein and CCL28 in individual animals did not appear to correlate.
An analysis done on the salivary glands from the experimental mice showed
that CCL 28 was not significantly changed in this tissue by the bromocryptine treatment (p=0.33). Since the mammary gland responded to the treatment and the salivary gland did not, the mechanism by which prolactin influences

CCL 28

gene ex-

pression is tissue specific. (Figure 3.2 and Figure 3.7).
3.3.1.2

Analysis of individual samples
In this analytical method, each sample was weighted equally. This means

that mice that had more reactions run on their tissue were weighted more than
mice that had fewer. All of the experimental and control data were then averaged
together for the final analysis.
In the mammary tissue, β-casein expression decreased an average of −0.67
(greater than six fold). Due to mouse-to-mouse variation, the variability of these
results was high, with a standard error of 0.25. (Figure 3.5.) A Student’s t test was
used to analyze whether or not the average decrease in β-casein was significantly
different from zero, which is the mean predicted by the null hypothesis. The p
value (one tailed) from this test was 0.01. This suggests that β-casein expression
was significantly reduced by the bromocryptine treatment.
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The average change in CCL 28 expression in the mammary gland was -1.31,
with a standard error of 0.23. (Figure 3.6). A student’s T test gave the significance
of

CCL 28

not being zero as p = 0.00. This finding demonstrates that prolactin sig-

naling regulates CCL 28 gene expression in vivo.
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Changes in Beta-casein expression
in the mammary gland
1.5
1
0.5

Control

0

Mouse F
Mouse G

-0.5

Mouse H
Mouse J

-1

Mouse L

-1.5
-2
-2.5

Figure 3.5: β-casein mRNA expression is consistently reduced in the mammary gland
in five mice treated with bromocryptine compared with the average two mice injected
with an alcohol control.

CCL28 expression in the mammary
gland of bromocryptine treated mice
0.5
0
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Control

-1

Mouse F

-1.5

Mouse H

-2

Mouse L

Mouse G
Mouse J

-2.5
-3

Figure 3.6: CCL 28 mRNA expression is consistently reduced in the mammary gland in
mice treated with bromocryptine.
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Change in salivary gland CCL28
expression

Average change in CCL28
expression

3
2.5
2
1.5
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1

H
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J

0

L

-0.5
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-1
-1.5
-2
-2.5
Experimental animals

Figure 3.7: CCL 28 mRNA expression is not consistently reduced in the salivary gland
in mice treated with bromocryptine.

3.3.1.3

Comparison of individual samples to controls
In this analysis, all of the control samples were gathered. These control data

were then compared as a group of data points (not pooled) to the individual samples. A Student’s t test examined the significance that the means between the control data and the experimental data were not the same. Using this method, the p
value given for β-casein’s being decreased was 0.01, while the p value for CCL 28’s
being decreased was 0.47. These results are very different from previous results,
which may reflect the wide variation between control samples. The control data
that were used to construct the control mean are listed in Table 3.3.
significant variation
3.3.2

Two day treatment
To determine whether a shorter treatment of more concentrated bromocryp-

tine would have the same effect as a long treatment at lower concentrations, we
injected mice for two days with a doubled concentration of bromocryptine. Using
this protocol, β-casein actually increased, although the differences between mice
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Mouse

Beta-casein Control samples

Control Q - PCR 1
Control Q - PCR 2
Control Q - PCR 3
Control Q - PCR 4
Average

CCL 28

Control samples

0.62
1.07
−0.5
0.58
0.44 ±0.33

−1.02
−1.39
0.68
0.16
−0.39 ±0.49

Table 3.3: Differences in control data points as compared against one control point.
All β-casein controls were compared to the same β-casein control point and all CCL 28
controls were compared to the same CCL 28 control.

were very large. (Average change in β-casein was 0.04, with a standard error of
1.24). The

CCL 28

expression did decrease (average of −0.79), but again the stan-

dard error was high (0.62).
Because the changes in expression in both β-casein and
ratic, this protocol was discontinued.
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CCL 28

were so er-

D ISCUSSION
CCL 28

is an important chemokine that mediates IgA ASC migration to the

lactating mammary gland. Its expression is dramatically increased during pregnancy and lactation, allowing antigen-specific B lymphocytes to migrate to the
mammary tissue where they can secrete IgA into the breast milk. Because

CCL 28

expression increases during the period of pregnancy and lactation when prolactin
levels are highest, combined with data showing prolactin regulates pIgR expression in the mammary gland [30], we hypothesized that prolactin also mediated
CCL 28

expression in the mammary gland. This study was designed to determine

if prolactin signaling increased the expression of

CCL 28.

This was done by both

adding prolactin to mammary cell lines in vitro and decreasing prolactin levels in
vivo.
In vitro studies were performed in mammary epithelial cell lines with both
Il-1β and prolactin. Neither appeared to have the ability to up-regulate CCL 28 expression. This is significant, as Il-1β has been shown to up-regulate CCL 28 in other
tissues, and there was a small but noticeable increase in Il-1β in the lactating mammary gland.
Both the RAW macrophage cell line and ex vivo peritoneal macrophages were
added to the mammary epithelial cells. Again, these macrophages did not appear
capable of up-regulating

CCL 28.

Because prolactin is known to stimulate Il-1β in

macrophages, prolactin was added to the macrophage/epithelial cell co-culture.
Importantly, β-casein was significantly up-regulated specifically in the prolactin
treated cells, demonstrating that prolactin signaling was occurring. Because the
prolactin was clearly able to induce and an up-regulation in β-casein, the fact that
CCL 28

was not up-regulated shows that prolactin alone is not sufficient to up-

regulate

CCL 28

expression in vitro. The lack of up-regulation cannot be due to a
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defect in the prolactin’s ability to signal. This suggests that there is an as yet undefined factor present in vivo that aids CCL 28 up-regulation.
A more conclusive in vivo study should be performed in a macrophagedepleted mouse to determine if macrophages play a greater role in regulating
CCL 28

expression in vivo. There are other hormones and cytokines inside a live an-

imal that may interact with macrophages to induce CCL 28 gene expression. Comparing CCL 28 levels in macrophage-depleted mice with wild type expression may
therefore show a greater role played by macrophages in CCL 28 regulation.
Although in vitro studies suggested that prolactin is not solely responsible
for CCL 28 up-regulation, in vivo experiments with mice showed a statistically significant decrease in

CCL 28

when bromocryptine, which decreases prolactin pro-

duction, was administered. This suggests that prolactin is a regulator of

CCL 28

expression during pregnancy and lactation, but that it may either work indirectly,
or require other factors present in vivo to exert its full effect. The analysis of the in
vivo experiments varied considerably depending on the method of analysis; this
is due to variation within the control samples. These discrepancies initially appear concerning, but it is important to remember that gene expression levels of
experimental animals were generated by using control tissues as calibrators. These
control tissues came from untreated mice, and were used as baseline data against
which experimental data points were analyzed. This approach was taken in order
to minimize the amount of variation seen as a result of random variations in QPCR
reactions.
In the future, DNAse treatments should be performed on the

RNA

sam-

ples in order to ensure that there is no genomic DNA contaminating the RNA,
as this would account for the occasional wildly varying control sample. The fact
that the data themselves have been reproducible suggests that maybe the outlying
data points that skew the averages may be due to genomic contamination. DNAse
treatments could easily remove any contaminating genomic DNA, reducing the
variation found in these results.
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In order to consistently reduce prolactin levels, bromocryptine must be administered for several days. Shorter treatments were not consistently able to decrease β-casein expression. Because the mice were only injected for two days, the
experiment is extremely sensitive to any error made in injecting the mice. The increased concentration of bromocryptine does not appear to compensate for the
decreased injection time period.
It is important to note that bromocryptine only had an effect on the
levels in the mammary gland. Salivary gland expression of

CCL 28

CCL 28

was not signif-

icantly changed. This suggests that prolactin specifically up-regulates the expression of

CCL 28

in the mammary gland without altering

CCL 28

expression in other

mucosal tissues. As only mammary tissue needs to attract a much higher level
of IgA secreting B cells during lactation, these results match perfectly with our
hypothesis that there must be a tissue-specific mechanism for controlling

CCL 28

up-regulation during pregnancy and lactation.
Future studies with more mice using the six day bromocryptine method
might help to clarify the role of prolactin in up-regulating

CCL 28.

In particular, it

would be interesting to see whether mice injected with both bromocryptine and
supplemental prolactin would continue to see a decrease in

CCL 28

expression. If

supplemental prolactin prevents the decrease of CCL 28 expression, it will confirm
prolactin’s significant role in controlling CCL 28 expression in the mammary gland.
This study explored the hormone mediated regulation of chemokines. Our
work suggests that the previously discovered mediators of intestinal
pression do not significantly up-regulate

CCL 28

CCL 28

ex-

expression in the lactating mam-

mary gland despite the fact that one of the best characterized factors, Il-1β, is
increased in the mammary gland during lactation. Our results also suggest that
prolactin mediates expression of the mucosal chemokine

CCL 28

in the mammary

gland. This is novel work in that this is the first study to suggest hormonal regulation of

CCL 28

gene expression, and to show that this regulation is tissue-specific.

This novel mechanism of

CCL 28

regulation helps to elucidate the mechanisms by

which IgA ASCs home to the mammary tissue during lactation.
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